| 2024年年报 | 2023年年报 | 2023年三季报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 医药商业(元) | 3,509,593,180.83 | 4,441,242,308.55 | 3,903,000,000.00 |
| 医药生产(元) | - | - | 4,610,000,000.00 |
| CMO/CDMO/CRO业务(元) | 7,961,268.81 | 25,668,179.00 | - |
| 医药制造(元) | 6,045,143,257.61 | 5,681,871,326.30 | - |
| 其他(元) | 8,933,795.19 | 8,763,132.04 | 188,000,000.00 |
| 营业成本(元) | |||
| 医药商业(元) | 2,828,389,092.24 | 3,891,823,019.70 | 3,385,000,000.00 |
| 医药生产(元) | - | - | 1,564,000,000.00 |
| CMO/CDMO/CRO业务(元) | 3,285,252.87 | 15,207,863.78 | - |
| 医药制造(元) | 2,396,602,976.41 | 2,094,206,689.90 | - |
| 其他(元) | 4,636,011.62 | 5,053,554.39 | 158,000,000.00 |
| 毛利(元) | |||
| 医药商业(元) | 681,204,088.59 | 549,419,288.85 | 518,000,000.00 |
| 医药生产(元) | - | - | 3,046,000,000.00 |
| CMO/CDMO/CRO业务(元) | 4,676,015.94 | 10,460,315.22 | - |
| 医药制造(元) | 3,648,540,281.20 | 3,587,664,636.40 | - |
| 其他(元) | 4,297,783.57 | 3,709,577.65 | 30,000,000.00 |
| 毛利率(%) | |||
| 医药商业(%) | 19.41 | 12.37 | 13.27 |
| 医药生产(%) | - | - | 66.07 |
| CMO/CDMO/CRO业务(%) | 58.73 | 40.75 | - |
| 医药制造(%) | 60.35 | 63.14 | - |
| 其他(%) | 48.11 | 42.33 | 15.96 |
| 收入构成(%) | |||
| 医药商业(%) | 36.67 | 43.72 | 44.86 |
| 医药生产(%) | - | - | 52.98 |
| CMO/CDMO/CRO业务(%) | 0.08 | 0.25 | - |
| 医药制造(%) | 63.16 | 55.94 | - |
| 其他(%) | 0.09 | 0.09 | 2.16 |
| 毛利构成(%) | |||
| 医药商业(%) | 15.70 | 13.24 | 14.41 |
| 医药生产(%) | - | - | 84.75 |
| CMO/CDMO/CRO业务(%) | 0.11 | 0.25 | - |
| 医药制造(%) | 84.09 | 86.42 | - |
| 其他(%) | 0.10 | 0.09 | 0.83 |